ABLYNX EXPANDS INTO NEW R&D FACILITIES
(Thomson Reuters ONE) -
GHENT, Belgium, 22 June 2010 - Ablynx [Euronext Brussels: ABLX] announced today
that it has moved into new R&D facilities located on the Technologiepark in
Zwijnaarde, near Ghent.
Ablynx will lease 8,000 m(2) of the brand new 10,000 m(2) building which is
located on the same Technologiepark as Ablynx's previous facilities.
"This new cutting-edge laboratory building will support Ablynx's growth in the
foreseeable future. This allows us to house our Belgian operations in one
facility", said Dr Edwin Moses, Chief Executive Officer and Chairman of Ablynx.
"With over 240 staff we believe Ablynx is one of the most advanced independent,
next-generation biologics companies."
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on the discovery and development of Nanobodies, a novel class of therapeutic
proteins based on single-domain antibody fragments, for a range of serious and
life-threatening human diseases. The Company currently has over 240 employees.
Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November
2007 and raised ?50 million through an SPO in March 2010.
Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of
major disease areas, including inflammation, thrombosis, oncology and
Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic
pipeline including four Nanobodies in clinical development. So far, Nanobodies
have been successfully generated against more than 190 different protein targets
including several complex targets such as chemokines, GPCRs, ion channels and
viruses, which are typically very difficult to address with conventional
monoclonal antibodies. Efficacy data have been obtained in 28 in vivo models for
Nanobodies against a range of different targets.
Ablynx has an extensive patent position in the field of Nanobodies for
healthcare applications. It has exclusive and worldwide rights to more than 130
families of granted patents and pending patent applications, including the
Hamers patents covering the basic structure, composition, preparation and uses
of Nanobodies.
For more information, please contact Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan(at)ablynx.com
[HUG#1426291]
Complete version of the press release: http://hugin.info/137912/R/1426291/374238.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Ablynx via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 22.06.2010 - 18:00 Uhr
Sprache: Deutsch
News-ID 22858
Anzahl Zeichen: 0
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX EXPANDS INTO NEW R&D FACILITIES"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
